TP53 and hepatocellular carcinoma: Due to the limited efficacy of ICB against hepatocellular carcinoma (HCC) and other cancers, researchers have developed a targeted mRNA nanoparticle platform designed to induce the expression of p53 (tumor suppressor gene) in HCC models.